Stelvio Therapeutics is a privately held, biotechnology company based in San Diego, California that was founded in 2017 by Attila Hajdu. The company focuses on developing a pipeline of alternative treatments for malignant glioblastoma multiforme (GBM), the most common and lethal brain tumor.
Stelvio's approach to treating cancer involves identifying compounds that drive the differentiation of cancer stem cells into benign cell types. It then induces the differentiation of tumor propagating cells into non-tumorigenic cells.
Johnson & Johnson Innovation
In March 2018, Stelvio Therapeutics joined Johnson & Johnson Innovation JLABS. Around the same time, i2020 Accelerator announced that Stelvio had joined its early drug discovery ecosystem to advance its proprietary epigenetic platform for glioblastoma therapies. i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year framework. It
Alexey V. Terskikh
Founder & CEO
i2020 to Accelerate Stelvio Therapeutics First-in-Class Epigenetic Platform for Glioblastoma
Stelvio Therapeutics joins JLABS San Diego
Tune in to IndieBio Accelerator's Demo Day today
Neesha A. Tambe
Documentaries, videos and podcasts
IndieBio SF Live Stream Demo Day 5 (9/14/2017)
September 14, 2017
- IndieBioA startup accelerator for biotechnology companies located in San Francisco, California.
- SOSVSOSV (formerly SOS Ventures) is a venture capital firm founded in 1995 by Sean O'Sullivan that provides growth, seed, and venture capital funding to startups. SOSV runs six seed accelerator programs: HAX Accelerator, Chinaccelerator, MOX, IndieBio, RebelBio, and Food-X.